QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...

Much of cell behavior is governed by the actions of biomolecular condensates: building block molecules that glom together and scatter apart as needed. Biomolecular condensates constantly shift their ...

Clene (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significant ...

In this week’s InnovationRx newsletter, the worsening measles outbreak, a noninvasive brain-computer implant, replacing heart ...

Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...

Kicked off in the game's late stages, the star allegedly missed Donnarumma's heroics during the last phase of the match when the Italian saved two penalty shots from Nunez and Jones.

A myotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects muscle control, and most ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...